Pay in 4 interest-free payments of $26.25 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
01-10 μM) blocks CK1ϵ-mediated PER3 nuclear localization mediated by CK1ϵ and suppresses PER2 degradation at 1 μM
5E)-1-((S)-2-amino-3-phenylpropanoyl)-3
InChi: InChI=1S/C18H19N3O6/c22-13-8-7-12(16(25)20-13)21-17(26)10-4-3-5-11(15(10)18(21)27)19-9-2-1-6-14(23)24/h3-5
Formula: C15H12O6
Chakrabarti G
Ruxolitinib (S) 05 trifluoroacetate 01-10 μM) blocks CK1ϵ-mediated PER3S Ruxolitinib is a less active enantiomer of Ruxolitinib, a JAK1 2 inhibitor. S Ruxolitinib was initially developed to target the constitutive activation of the JAK STAT pathway. Janus kinases (JAKs) are a family of cytoplasmic tyrosine kinases that mediates signals from the receptors for various cytokines and growth factors that have a key role in haematopoiesis and immune function. Ruxolitinib maintains its anti JAK activity by competitive
US$ 5705.00
US$ 261.00
US$ 198.00
US$ 1830.00
US$ 312.95
US$ 157.50
US$ 1395.00